Ultragenyx Pharma (RARE) Tops Q4 EPS by 18c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.52), $0.18 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $127.39 million versus the consensus estimate of $119.38 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results